Interim report
Page 1
Diamyd Medical AB (publ.) Box 7349 • SE-103 90 Stockholm, Sweden • Phone +46 8-661 00 26 www.diamyd.com • info@diamyd.com YEAR -END REPORT September 2025 – August 2026 Diamyd Medical AB (publ), Fiscal year 2025/2026
Page 2
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 2 Financial summary (September 2025 – August 2026) • Net sales: MSEK 0.5 (0.1), fourth quarter: MSEK 0.1 (0.0) • Net result: MSEK -255.6 (-169.8), fourth quarter: MSEK -16.8 (-44.9) • Result per share before and after dilution: SEK -1.8 (-1.5), fourth quarter: SEK -0.1 (-0.3) • Cash flow from operating activities: MSEK -195.3 (-169.7), fourth quarter: MSEK -40.4 (-35.9) • Cash and short-term investments on August 31, 2026: MSEK 305.4 (277.2) • The Board proposes that no dividend be paid for the financial year 2025/26 Events during the fourth quarter (June – August 2026) • Diamyd Medical provided an update on ongoing activities • Diamyd Medical received ‘Notice of Allowance’ for Key Precision Medicine Patent in the US • Diamyd Medical provided an update regarding strategic overview • Mathias Skalmstad started the position as CFO for Diamyd Medical • Diamyd Medical provided an update on learnings from DIAGNODE-3 interim analysis Events after the fourth quarter • ASSET partnership, coordinated by Diamyd Medical, concluded five-year innovation program with final conference on precision medicine and the future of screening • Diamyd Medical announced that results from the DiAPREV-IT study, published in journal Diabetologia, show that Diamyd’s recombinant retogatein delays the onset of insulin- dependent type 1 diabetes by more than five years
Page 3
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 3 Comments by CEO Dear Shareholders, The past year has been one of challenges, discipline, and renewed focus for Diamyd Medical. Following the decision to close the DIAGNODE-3 study, we acted decisively to reduce costs, preserve our financial strength, and reassess where we believe the company can create the greatest shareholder value. Expenses associated with closing the study have now been taken, and based on our approved budget, our current cash position is expected to fund operations for more than two years. I am pleased to share encouraging news regarding our retogatein (GAD -alum) drug candidate. A peer-reviewed publication in Diabetologia reported that retogatein may delay progression from early, non-insulin-requiring Type 1 Diabetes (Stage 1 and 2 T1D) to insulin-requiring Stage 3 disease by more than five years in a genetically defined subgroup. This randomized study evaluated individual s with GAD autoantibodies and at least one additional islet autoantibody who had not yet progressed to insulin- requiring disease. With this finding, Diamyd Medical is actively engaging with clinical investigators on the potential design of clinical trials seeking to identify individuals who match retogatein’s genetically defined responder profile, persons who could represent a relevant population for future treatment. We are also continuing discussions with pharmaceutical companies that see potential strategic value in retogatein as a complement to their metabolic and autoimmune disease portfolios. Given our strong cash position, we also evaluated a range of investment opportunities during the past quarter, both within and outside Type 1 Diabetes therapeutics, including other autoimmune disease areas. This process reaffirmed our belief that the company's greatest strengths reside in its current drug candidates, including retogatein. Retogatein has demonstrated a favorable safety profile across more than 15 clinical studies involving over 1,000 patients. Together with the encouraging results described above, these data strengthen our interest in developing retogatein as a potential therapy to delay or prevent progression to insulin-requiring Type 1 Diabetes. We believe this represents a logical path forward for Diamyd Medical to pursue. Another potential target population is patients with Latent Autoimmune Diabetes in Adults (LADA), whi ch may account for approximately 10% of patients initially diagnosed with Type 2 Diabetes and may instead have autoimmune diabetes. We also remain open to participating with retogatein in investigator -initiated studies, and several discussions are ongoing. Taken together, the characteristics of retogatein provide a compelling basis for continued development: a long-term efficacy signal extending beyond five years; antigen-specific immune tolerance rather than broad immunosuppression; a favorable safety prof ile; an identified genetically defined responder group; and straightforward administration for patients. Our GMP-approved biomanufacturing facility in Umeå is operational, with the next batch of retogatein drug substance scheduled for production before the end of the year. Diamyd Medical is open to working with partners on Contract Development and Manufacturing Organization projects, including those that contribute to preparedness and manufacturing capabilities in the event of future pandemics and other biological threats. The company intends to remain open to selected, limited investments that have the potential to generate additional value over a two- to three-year horizon. Diamyd Medical currently holds investments in NextCell Pharma and Waterise. Another recently formed initiative is the company's development of DiaTrapper, an AI -based application trained using datasets from various Type 1 Diabetes-related research efforts. The application is one outcome of the Vinnova-financed ASSET project. It is intended to assess an individual's risk of progressing to Stage 3 Type 1 Diabetes over time. Our priorities are clear: advance retogatein toward the market for the early stages of Type 1 Diabetes; expand our Biomanufacturing activities in Umeå to include additional projects; continue and broaden partner discussions; and remain open to limited investments in promising assets.
Page 4
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 4 I look forward to the coming years with great enthusiasm. The long -term data strengthen our conviction that retogatein deserves continued development. At the same time, our financial position and focused strategy provide Diamyd Medical with a disciplined pathway to pursue that opportunity. I strongly believe in retogatein and its potential to make a meaningful difference for people at risk of progressing to insulin -requiring Type 1 Diabetes. This optimism would not be possible without the support of two special groups deserving our appreciation. First, I thank our more than 18,000 shareholders and supporters, including Breakthrough T1D, for their continued support. I also want to express my sincere gratitude to the over 1,000 patients who have participated in clinical studies with retogatein as part of our efforts to combat autoimmune Type 1 Diabetes. Stockholm, October 7, 2026 Anders Essen-Möller, CEO Drugs in clinical development Retogatein is an antigen-specific, immunomodulatory precision medicine in clinical development for the treatment and prevention of type 1 diabetes. Retogatein has shown safety in clinical studies with more than 1,000 patients and has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (symptomatic) type 1 diabetes. Retogatein has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) type 1 diabetes. The Phase 3 trial DIAGNODE-3 and the Phase 2 trial DiaPrecise are both early terminated. The decision was taken in spring 2026 after the predefined interim efficacy analysis in DIAGNODE-3 did not demonstrate statistical significance on the primary efficacy endpoint. In addition, the pre-specified criteria for continuation of the trial were not met. Based on these results, the Company has decided to close DIAGNODE-3 for futility. Retogatein has recently been reported to delay disease progression into Stage 3 Diabetes and may be reassessed for prevention of Stage 3. Remygen® is an oral investigational medicine based on GABA with potential regenerative and immunomodulatory effects for the treatment of type 1 and type 2 diabetes. The safety of Remygen® has been demonstrated in a Phase 1/2 clinical trial with Remygen® in individuals who have had type 1 diabetes for several years.
Page 5
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 5 Biomanufacturing in Umeå A biomanufacturing facility for biological products has been established in Umeå, Sweden. The facility is primarily developed for the manufacture of recombinant GAD65, the active pharmaceutical ingredient (API) in the Precision Medicine immunotherapy retogatein candidate. GMP certification and manufacturing authorization to produce clinical material were approved in May 2026. The approximately 24,000 square foot multipurpose site includes clean rooms, laboratory facilities, warehousing, and office space, providing strong capabilities for scalable and controlled biomanufacturing. Diamyd Medical has implemented Cytiva’s configurable single-use bioprocess platform FlexFactory, based on a baculovirus-insect cell expression system. Going forward, the facility may serve as a strategic manufacturing resource for biological substances in both internal and external pharmaceutical development projects. Additional opportunities will be evaluated to maximize the value of the facility, manufacturing platform, analytical laboratory, and in-house expertise. “I am very proud of the team’s efforts in establishing the manufacturing facility and successfully obtaining GMP certification for the manufacture of materials for clinical use” Sofia Mayans, PhD, Head of Manufacturing Site The employees at the Umeå facility are experts in recombinant manufacture of biologics, e.g., cell culture and protein purification, paving the way for new clinical trial materials.
Page 6
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 6 Key figures for the Group 3 months Jun-Aug 2025/26 3 months Jun-Aug 2024/25 12 months Sep-Aug 2025/26 12 months Sep-Aug 2024/25 Research and development costs, MSEK 0.4 -30.5 -180.1 -119.5 Liquid assets and short-term investments, MSEK 305.4 277.2 305.4 277.2 Solidity, % 67 79 67 79 Result per share, before and after dilution, SEK -0.1 -0.3 -1.8 -1.5 Liquidity and short-term investment per share, SEK 2.0 2.0 2.0 2.0 Equity per share, SEK 1.6 2.0 1.6 2.0 Total Cash flow per share, SEK 0.0 -0.3 0.2 1.5 Share price per closing, SEK 1.02 11.30 1.02 11.30 Number of shares per closing 154 984 500 137 499 723 154 984 500 137 499 723 Average numbers of shares 154 984 500 137 499 723 145 174 897 112 524 911 Average number of employees 39 36 42 33
Page 7
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 7 Consolidated statement of comprehensive income KSEK Note 3 months Jun-Aug 2025/26 3 months Jun-Aug 2024/25 12 months Sep-Aug 2025/26 12 months Sep-Aug 2024/25 OPERATING INCOME Net sales 65 18 478 130 Other operating income 2 1 355 839 4 205 4 885 TOTAL OPERATING INCOME 1 420 857 4 682 5 015 OPERATING EXPENSES External research and development costs* 439 -30 477 -180 128 -119 504 External patent- and license costs -73 -718 -2 761 -3 835 Personnel costs 3 -12 230 -9 860 -52 380 -39 224 Other external costs 4 -4 050 -4 258 -18 451 -17 327 Other operating expenses -295 -303 -1 516 -1 855 Depreciation and impairment of tangible and intangible assets -1 729 -1 755 -7 023 -6 504 TOTAL OPERATING EXPENSES -17 939 -47 372 -262 259 -188 251 OPERATING RESULT -16 519 -46 514 -257 577 -183 236 FINACIAL INCOME AND EXPENSES Profit/loss of sold shares or other securities -46 - 438 7 465 Impairment of participation in other companies -88 - -88 -508 Impairment of participation in associated companies - - -1 264 - Interest income and similar profit items 1 739 1 650 6 421 10 204 Interest expense and similar loss items -1 896 - -3 523 -3 702 TOTAL FINANCIAL INCOME AND EXPENSES -291 1 650 1 984 13 459 RESULT AFTER FINANCIAL INCOME AND EXPENSES -16 810 -44 864 -255 593 -169 777 Income tax - - - - NET RESULT FOR THE PERIOD -16 810 -44 864 -255 593 -169 777 *The provision for close-down costs related to DIAGNODE-3 was adjusted during the quarter and amounted to approximately 32,509 KSEK as of the reporting date. .
Page 8
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 8 Consolidated balance sheet KSEK Note 31 Aug 2026 31 Aug 2025 ASSETS NON-CURRENT ASSETS Intangible assets Patents - - Tangible assets Land and buildings 27 429 28 837 Constructions in progress - 988 Machinery and equipment 19 219 22 877 Financial assets 5 Deferred tax 132 193 Participation in associated companies - 1 264 Participation in other companies 9 162 5 984 Other long-term receivables - 91 TOTAL NON-CURRENT ASSETS 55 943 60 233 CURRENT ASSETS Trade receivables 57 - Other receivables 2 650 4 093 Prepaid expenses and accrued income 1 177 11 126 Liquid assets 305 426 277 185 TOTAL CURRENT ASSETS 309 310 292 404 TOTAL ASSETS 365 253 352 638
Page 9
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 9 KSEK Note 31 Aug 2026 31 Aug 2025 EQUITY AND LIABILITIES EQUITY Share capital 15 719 13 945 Other contributed capital 1 099 579 884 668 Other equity incl. result for the year -871 710 -618 615 TOTAL EQUITY 243 588 279 999 PROVISIONS Pensions and other obligations - 113 Other provisions 32 509 - TOTAL PROVISIONS 32 509 113 LONG TERM-LIABILITIES Other long-term liabilities 6 55 090 45 043 TOTAL LONG-TERM LIABILITIES 55 090 45 043 CURRENT LIABILITIES Trade payables 20 914 11 962 Other payables 6 289 7 916 Prepaid income and accrued expenses 6 863 7 605 TOTAL CURRENT LIABILITIES 34 066 27 483 TOTAL EQUITY AND LIABILITIES 365 253 352 638
Page 10
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 10 Consolidated statement of cash flow KSEK Note 3 months Jun-Aug 2025/26 3 months Jun-Aug 2024/25 12 months Sep-Aug 2025/26 12 months Sep-Aug 2024/25 OPERATING ACTIVITIES Operating profit/loss -16 519 -46 514 -257 577 -183 236 Interest received 820 7 067 5 068 8 517 Interest paid -1 896 -2 631 -2 837 -2 631 Non-cash flow items Depreciation 1 729 1 645 7 023 6 504 Other non-cash flow items -37 783 941 35 033 2 043 CASH FLOW FROM OPERATING ACTIVITIES BEFORE -53 649 -39 492 -213 290 -168 803 CHANGES IN WORKING CAPITAL Increase (-) decrease (+) accounts receivable -20 41 -57 23 Increase (-) decrease (+) other receivables 1 265 2 687 1 444 -1 388 Increase (-) decrease (+) prepaid expenses/accrued income 650 2 969 9 949 12 924 Increase (-) decrease (+) trade payables 13 802 -1 027 8 953 -4 644 Increase (-) decrease (+) other liabilities -1 431 -467 -1 566 -901 Increase (+) decrease (-) accrued expenses/deferred income -1 022 -656 -743 -6 894 NET CASH FLOW FROM OPERATING ACTIVITIES -40 405 -35 944 -195 311 -169 683 INVESTING ACTIVITIES Investment in tangible assets - -2 184 -992 -10 048 Investment in financial assets -4 446 - -4 446 -608 Disposal of financial assets 1 058 - 1 132 1 008 Profit on disposal of financial assets - - 485 7 211 Matured short-term investments -159 008 - -99 371 19 608 Investment in short term investments 198 741 - 99 371 - NET CASH FLOW FROM INVESTING ACTIVITIES 36 345 -2 184 -3 820 17 171 FINANCING ACTIVITIES New issue - - 233 247 315 392 Issue expense - -567 -16 589 -13 441 Long-term liabilities 6 1 896 -507 10 047 14 371 NET CASH FLOW FROM FINANCING ACTIVITIES 1 896 -1 074 226 705 316 322 TOTAL CASH FLOW FOR THE PERIOD -2 165 -39 202 27 574 163 810 Cash and cash equivalents at beginning of period 306 672 319 262 277 185 112 758 Net foreign exchange difference 919 -2 874 667 617 CASH AND CASH EQUIVALENTS AT END OF PERIOD 305 426 277 185 305 426 277 185
Page 11
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 11 Consolidated statement of changes in equity KSEK Share Capital Other contributed capital Other equity incl. result for the year Total Shareholders’ equity OPENING BALANCE SEPTEMBER 1, 2024 10 114 586 549 -450 742 145 920 Net result - - -169 777 -169 777 New issue 3 831 311 561 - 315 392 Issue expenses - -13 441 - -13 441 Incentive program LTI 2022 3 - - 911 911 Incentive program LTI 2024 3 - - 875 875 Incentive program Board LTI 2024 3 - - 119 119 CLOSING BALANCE AUGUST 31, 2025 13 945 884 668 -618 614 279 999 OPENING BALANCE SEPTEMBER 1, 2025 13 945 884 668 -618 614 279 999 Net result - - -255 593 -255 593 New issue 1 747 231 500 - 233 247 Issue expenses - -16 589 - -16 589 Incentive program LTI 2022 3 26 - 573 599 Incentive program LTI 2024 3 - - 1 712 1 712 Incentive program Board LTI 2024 3 - - 212 212 CLOSING BALANCE AUGUST 31, 2026 15 719 1 099 579 -871 710 243 588
Page 12
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 12 Income statement for the parent company KSEK Note 3 months Jun-Aug 2025/26 3 months Jun-Aug 2024/25 12 months Sep-Aug 2025/26 12 months Sep-Aug 2024/25 OPERATING INCOME Net sales 112 105 748 525 Other operating income 2 1 355 839 4 205 4 885 TOTAL OPERATING INCOME 1 467 944 4 953 5 410 OPERATING EXPENSES External research and development costs* 439 -30 477 -180 128 -119 504 External patent- and license costs -73 -718 -2 761 -3 835 Personnel costs 3 -12 230 -9 860 -52 380 -39 224 Other external costs 4 -4 685 -4 743 -20 765 -18 080 Other operating expenses -295 -303 -1 516 -1 855 Depreciation and impairment of Tangible and intangible assets -1 270 -1 241 -5 066 -4 388 TOTAL OPERATING EXPENSES -18 115 -47 343 -262 616 -186 887 OPERATING RESULT -16 648 -46 399 -257 664 -181 477 FINANCIAL INCOME AND EXPENSES Profit/loss of sold shares or other securities -46 - 438 7 465 Impairment of shares in associated companies - - -1 264 - Impairment of participation in other companies -88 - -88 -508 Interest income and similar profit items 1 854 1 841 6 952 10 998 Interest expense and similar loss items -1 896 - -3 523 -3 702 TOTAL FINANCIAL INCOME AND EXPENSES -176 1 841 2 516 14 253 RESULT BEFORE TAXES -16 824 -44 557 -255 148 -167 225 Income tax - - - - NET RESULT FOR THE PERIOD -16 824 -44 557 -255 148 -167 225 * The provision for close-down costs related to DIAGNODE-3 was adjusted during the quarter and amounted to approximately 32,509 KSEK as of the reporting date.
Page 13
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 13 Balance sheet for the parent company KSEK Not 31 Aug 2026 31 Aug 2025 ASSETS NON-CURRENT ASSETS Intangible assets Patents - - Tangible assets Machinery and equipment 18 959 23 263 Financial assets 5 Shares in subsidiaries 16 291 16 291 Long-term receivables from subsidiaries 15 000 15 000 Participation in associated companies - 1 264 Participation in other companies 9 163 5 984 Other long-term receivables - 91 TOTAL NON-CURRENT ASSETS 59 413 61 892 CURRENT ASSETS Trade receivables 41 - Receivables subsidiaries 238 809 Other receivables 2 517 3 972 Prepaid expenses and accrued income 1 155 11 095 Liquid assets and short-term investments 304 108 276 443 TOTAL CURRENT ASSETS 308 059 292 319 TOTAL ASSETS 367 472 354 211
Page 14
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 14 KSEK Not 31 Aug 2026 31 Aug 2025 EQUITY AND LIABILITIES EQUITY Restricted equity Share capital 15 719 13 945 Statutory reserve 200 200 Non restricted equity Share premium reserve non-restricted 1 099 379 884 468 Profits or loss brought forward -613 886 -449 158 Net result for the period -255 148 -167 225 TOTAL EQUITY 246 264 282 231 PROVISIONS Pensions and other obligations - 113 Other provisions 32 509 - TOTAL PROVISIONS 32 509 113 LONG-TERM LIABILITIES Other long-term liabilities 6 55 090 45 043 TOTAL LONG-TERM LIABILITIES 55 090 45 043 CURRENT LIABILITIES Trade payables 20 870 11 597 Other payables 5 946 7 622 Payables subsidiaries - - Prepaid income and accrued expenses 6 793 7 605 TOTAL CURRENT LIABILITIES 33 609 26 824 TOTAL EQUITY AND LIABILITIES 367 472 354 211
Page 15
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 15 Notes Note 1 – General information and accounting principles This interim report includes the parent company Diamyd Medical AB (publ), Corp. Reg. No. 556242 -3797 and the subsidiary Diamyd Biomanufacturing AB, Corp. Reg. No. 559041-0931. Unless otherwise stated, all amounts are in thousands of Swedish kronor (KSEK). Figures, if not otherwise stated, refer to the Group. Interim and annual reports are prepared with the application of the Annual Accounts Act and the Swedish Accounting Standards Board BFNAR 2012: 1 Annual Report and Consolidated accounts (K3). Note 2 – Other operating income Other operating income consists mainly of grants related to VINNOVA (Swedish innovation agency) financed projects. Note 3 – Long-term Incentive programs LTI 2022 Incentive program LTI2022 was finalized during the financial year, and shares were allocated to participants at quota value. LTI 2024 The Company had as of August 31, 2026, allocated 45 participants rights to performance shares in accordance with LTI 2024. A total of 450 000 rights to performance shares have been allocated. LTI 2024 rights are measured on the allotment date at fair value of allocated equity instruments. As of August 31, 2026, social costs for LTI 2024 amounted to MSEK 0.0 and personnel costs MSEK 1.71 for the period. The personnel cost was based on the allocation value, simulated with the Monte Carlo method. Board LTI 2024 The Company had as of August 31, 2026, allocated 6 participants rights to performance shares in accordance with Board LTI 2024. A total of 60 000 rights to performance shares have been allocated. Board LTI 2024 rights are measured on the allotment date at fair value of allocated equity instruments. As of August 31, 2026 , social costs for Board LTI 2024 amounted to MSEK 0.0 and personnel costs MSEK 0.21 for the period. The personnel cost was based on the allocation value, simulated with the Monte Carlo method. Note 4 – Related-party transactions During the period companies represented by immediate family members of the main owner and Executive Chairman Anders Essen-Möller were contracted as consultants. Total compensation for consultancy services and salaries to immediate family members amounted to KSEK 2 267 (2 229). Anders Essen-Möller has through a company owned by Essen-Möller been compensated by KSEK 794 (3 257). Pricing has been set by the arm’s length principle. Group and parent company KSEK Sep-Aug 2025/26 Sep-Aug 2024/25 Consultant fees and salary to related parties 2 267 2 229 Consultant fees to Board members 794 3 257
Page 16
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 16 Note 5 – Financial assets Parent company Diamyd Medical AB owns shares in NextCell Pharma AB (corporate registration no 556965- 8361) who develops stem cell therapies and operates a stem cell bank for private family saving of stem cells . As of August 31, 2026, the carrying amount was MSEK 4.7. Diamyd Medical’s share of the equity as well as share of the votes was approximately 4 %, as of the same date. Diamyd Medical AB owns preference shares in Waterise B.V. (trade register number 88419398) who specialize in providing sustainable freshwater solutions through innovative desalination technology. As of August 31, 2026, the carrying amount was MSEK 4.4. Note 6 – Long-term liabilities Group and parent company KSEK Sep-Aug 2025/26 Sep-Aug 2024/2025 Opening balance (Breakthrough T1D) 45 043 30 672 Other long-term liabilities (Breakthrough T1D) 10 047 14 371 Closing balance 55 090 45 043 Diamyd Medical receives financing within its partnership with Breakthrough T1D (formerly JDRF), when certain milestones have been reached. If Diamyd Medical obtains commercial approval for retogatein and sales of the drug are commercially successful, Breakthrough T1D will receive limited royalties. As a result of Diamyd Medical’s commitment pertaining to future royalties, payments from Breakthrough T1D are recognized as long- term liabilities. Risks Diamyd Medical’s operations are associated with risks related to inter alia drug development, commercialization, financing, intellectual property, collaborations with partners, authority decisions, agreements, and key personnel. For a description of the Company’s risks, please see the Annual Report for the fiscal year 2024/2025. No significant changes in the Company’s risk assessment have occurred since the Annual Report was issued.
Page 17
DIAMYD MEDICAL AB YEAR-END REPORT September 2025 – August 2026 17 Statement The Board of Directors and the CEO certify that this interim report gives a fair overview of the business, position and profit or loss of the Company and describes the principal risks and uncertainties that the Company faces. This report has not been reviewed by the Company’s auditors. Stockholm, October 7, 2026 Erik Nerpin Anders Essen-Möller Chairman of the Board CEO, Board member Maria-Teresa Essen-Möller Torbjörn Bäckström Board member Board member Mark A. Atkinson Karin Hehenberger Board member Board member Karin Rosén Board member Financial Calendar Annual Report November 12, 2026 Annual General Meeting December 3, 2026 Quarterly Report 1 January 26, 2027 Quarterly Report 2 April 27, 2027 Quarterly Report 3 June 29, 2027 Year-end Report October 26, 2027 About Diamyd Medical Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The company’s lead investigational drug candidate is retogatein (GAD - alum), based on recombinant GAD65. The Company has established a GMP-approved facility for manufacturing of biological products in Umeå, Sweden. Diamyd Medical’s B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser. Further information is available on https://www.diamyd.com For more information, please contact: Anders Essen-Möller, CEO, anders.essen-moller@diamyd.com Diamyd Medical AB (publ), Box 7349, SE-103 90 Stockholm, Sweden Phone: +46 8 661 00 26 E-mail: mailto:info@diamyd.com Reg. no: 556242-3797 The information was submitted for publication, through the agency of the contact persons set out above, at 08.15 CET on October 7, 2026.